Not currently recruiting at UCSF
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia
Summary
- Eligibility
- for people ages 4 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jacque Duncan
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jacque Duncan
Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Applied Genetic Technologies Corp
- Links
- Sponsor website
- ID
- NCT02599922
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Last Updated